News
If the agency approves its application, the firm will begin a Phase I clinical trial in c-MYC-driven cancers in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback